



November 25, 2025

Company Name: AnGes Inc.

Presentative: Ei Yamada, President & CEO

Notice Regarding Additional Agreement for Co-Developed Tie2 Receptor Agonist (AV-001)

AnGes Inc. is pleased to announce that the company has entered into an agreement with Vasomune Therapeutics, Inc. (headquartered in Canada, represented by CEO Dr. Brian E. Jahns, hereinafter “Vasomune”) to expand the indications for the Tie2 receptor agonist (Pegevongitide AV-001, hereinafter “AV-001”) currently under joint development.

To date, the company has been conducting clinical trials of AV-001 in collaboration with Vasomune, targeting acute respiratory distress syndrome (ARDS), including viral and bacterial pneumonia. Furthermore, on September 4 of this year, the company announced the initiation of a physician-led study to evaluate AV-001’s potential to mitigate cytotoxic brain edema caused by hemodialysis and to preserve white matter function in the brain.

Based on the mechanism of AV-001, which stabilizes blood vessels and suppresses vascular leakage and inflammation, the company and Vasomune have assessed its potential applicability to other conditions, including cognitive impairment associated with hemodialysis. As a result, we have agreed to expand the scope of our joint development agreement to include all disease indications.

Under this agreement, the company will pay Vasomune USD 1 million (JPY 157 million at an exchange rate of JPY 157/USD) by the end of 2025, and an additional USD 3 million (JPY 471 million at the same exchange rate) between 2026 and 2027.

Please note that this agreement does not affect our consolidated earnings forecast for the fiscal year ending December 2025. Should any matters requiring disclosure arise in the future, we will promptly provide updates.